Capecitabine Clinical Trial
Official title:
Clinical Effect Analysis of Different Regimens of Capecitabine in the Treatment of Patients With Advanced Colon Cancer
Verified date | January 2024 |
Source | Jingjiang People's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To observe the clinical efficacy and adverse reactions of capecitabine in the treatment of advanced colon cancer. A total of 150 patients with advanced colon cancer were selected by convenience sampling and then were divided into the control group (n = 50), the medium-dose group (n = 50), and the low-dose group (n = 50) using a random number table.Different administration regimens of capecitabine were given, and the treatment course was appropriately extended. The therapeutic effect and incidence of adverse reactions were observed.
Status | Completed |
Enrollment | 150 |
Est. completion date | January 22, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 69 Years |
Eligibility | Inclusion Criteria: - According to the diagnostic criteria for colon cancer in the Consensus on Screening, Diagnosis and Treatment of Early Colorectal Cancer and Precancerous Lesions in China , colon cancer was confirmed by pathology - TNM(tumor node metastasis) clinical stage was III or IV - Predicted survival period > 3 months Exclusion Criteria: - Patients with heart, liver, kidney and other important organ failure and contraindications to chemotherapy - Patients who received other anti-tumor therapy before admission - The disease progressed rapidly and could not be successfully completed by this researcher - Allergic to related drugs |
Country | Name | City | State |
---|---|---|---|
China | Clinical effect analysis of different regimens of capecitabine in the treatment of patients with advanced colon cancer | Jingjiang | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Jingjiang People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical efficacy:Overall response rate(RR%) | Overall response rate (RR%): complete response (CR) + partial response (PR)/total number of cases×100%. | After the end of all treatment cycles (3 weeks per cycle, a total of four cycles, totaling 84 days) | |
Primary | Clinical efficacy:Disease control rate(DR)% | Disease control rate (DR)% = (CR+PR+SD)/total number of cases×100%. | After the end of all treatment cycles (3 weeks per cycle, a total of four cycles, totaling 84 days) | |
Primary | Quality of life:QLQ-C30(Quality of Life Questionnaire-core30) Score | Quality of life was scored using the QLQ-C30 (Quality of Life Questionnaire-core30).QLQ-C30 is composed of one global quality of life scale and five functional scales, which include physical function, role function, emotional function, cognitive function, and social function. Scoring criteria: After the scores of each part of the scale were converted to standardized scores, the scores ranged from 0 to 100, and the higher the score of the scale, the better the overall quality of life and functional status. | After the end of all treatment cycles (3 weeks per cycle, a total of four cycles, totaling 84 days) | |
Primary | Incidence of adverse reactions | Adverse reactions include hand-foot syndrome, stomatitis, leukopenia, nausea and vomiting, bone marrow suppression, and pigmentation. Incidence of adverse reactions%=number of adverse reaction cases/total number of cases × 100% | After the end of all treatment cycles (3 weeks per cycle, a total of four cycles, totaling 84 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03079427 -
Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma
|
Phase 2 | |
Completed |
NCT03079440 -
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT05290194 -
Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT03889626 -
The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer
|
Phase 3 | |
Recruiting |
NCT06169202 -
A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
|
||
Not yet recruiting |
NCT05841134 -
Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT05970302 -
XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
|
Phase 2 | |
Recruiting |
NCT05022030 -
First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes
|
Phase 2 | |
Recruiting |
NCT06202014 -
Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC
|
Phase 2 | |
Enrolling by invitation |
NCT03030508 -
Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal Patients
|
N/A | |
Recruiting |
NCT02012634 -
Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
|
Phase 3 | |
Active, not recruiting |
NCT06188000 -
Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Capecitabine
|
N/A | |
Completed |
NCT04720131 -
Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.
|
Phase 2 | |
Active, not recruiting |
NCT03258099 -
Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Recruiting |
NCT05535413 -
UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03500380 -
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
|
Phase 2/Phase 3 | |
Recruiting |
NCT06405490 -
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
|
Phase 2 |